Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Sny crawled date : 2021 - 11 - 22 save search
Neurocrine Commits Potential $2.6 Billion to Sosei Heptares, Neuropsychiatric Disorders
Published: 2021-11-22 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
order potential neuropsychiatric
Neurocrine Commits Up to $2.6 Billion to Sosei Heptares, Neuropsychiatric Disorders
Published: 2021-11-22 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
order neuropsychiatric
Neurocrine Commits Potential $2.6 Billion to Sosei Heptares, Neuropsychiatric...
Published: 2021-11-22 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
potential neuropsychiatric
Neurocrine Commits $2.6 Billion+ to Sosei Heptares, Neuropsychiatric Disorders
Published: 2021-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
order neuropsychiatric
Despite Positive Phase II Data, Connect Derm Drug Faces Tough Market
Published: 2021-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
positive drug
Despite Hitting Mark in Phase II Dermatitis Study, Connect Bio’s Stock Plunged 55%
Published: 2021-11-22 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
dermatitis
Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines
Published: 2021-11-22 (Crawled : 13:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BIDU | $95.025 -0.58% -0.58% 1.8M
|
Technology Services
|
| O: -1.31%
H: 0.0%
C: 0.0%
vaccine license therapeutics
Teal Bio, Inc. Announces Oversubscribed Series A Funding Round
Published: 2021-11-22 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
funding
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.